1-t-butyl 2-methyl (2S,4R)-4-[(5-bromo-2-phenylquinolin-4-yl)oxy]pyrrolidine-1,2-dicarboxylate | 1020094-40-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-t-butyl 2-methyl (2S,4R)-4-[(5-bromo-2-phenylquinolin-4-yl)oxy]pyrrolidine-1,2-dicarboxylate
• CAS: 1020094-40-9
• 化学式: C₂₆H₂₇BrN₂O₅
• 分子量: 527.415
• InChiKey: VPSAPUPLFZFTDE-UTKZUKDTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.59
• 重原子数：
  34.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  77.96
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  1-t-butyl 2-methyl (2S,4R)-4-[(5-bromo-2-phenylquinolin-4-yl)oxy]pyrrolidine-1,2-dicarboxylate 、 三丁基乙烯基锡 在 四(三苯基膦)钯 作用下， 以 甲苯 为溶剂， 反应 3.0h， 以89%的产率得到methyl N-[(pent-4-en-1-yloxy)carbonyl]-L-norleucyl-(4R)-4-[(5-bromo-2-phenylquinolin-4-yl)oxy]-L-prolinate
  参考文献：
  名称：

  Molecular Modeling Based Approach to Potent P2−P4 Macrocyclic Inhibitors of Hepatitis C NS3/4A Protease

  摘要：

  Molecular modeling of inhibitor bound full length HCV NS3/4A protease structures proved to be a valuable tool in the design of a new series of potent NS3 protease inhibitors. Optimization of initial compounds provided 25a. The in vitro activity and selectivity as well as the rat pharmacokinetic profile of 25a compare favorably with the data for other NS3/4A protease inhibitors currently in clinical development for the treatment of HCV.

  DOI：

  10.1021/ja711120r
• 作为产物：
  描述：

  5-bromo-2-phenylquinolin-4(1H)-one 、 1-tert-butyl 2-methyl (2S,4S)-4-{[(4-bromo-phenyl)sulfonyl]oxy}-pyrrolidine-1,2-dicarboxylate 在 caesium carbonate 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 3.0h， 以91%的产率得到1-t-butyl 2-methyl (2S,4R)-4-[(5-bromo-2-phenylquinolin-4-yl)oxy]pyrrolidine-1,2-dicarboxylate
  参考文献：
  名称：

  Molecular Modeling Based Approach to Potent P2−P4 Macrocyclic Inhibitors of Hepatitis C NS3/4A Protease

  摘要：

  Molecular modeling of inhibitor bound full length HCV NS3/4A protease structures proved to be a valuable tool in the design of a new series of potent NS3 protease inhibitors. Optimization of initial compounds provided 25a. The in vitro activity and selectivity as well as the rat pharmacokinetic profile of 25a compare favorably with the data for other NS3/4A protease inhibitors currently in clinical development for the treatment of HCV.

  DOI：

  10.1021/ja711120r